Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) Director Joseph Jr. Manko purchased 30,367 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $0.89 per share, with a total value of $27,026.63. Following the completion of the acquisition, the director owned 2,309,775 shares in the company, valued at approximately $2,055,699.75. This trade represents a 1.33% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Myomo Stock Performance
Shares of Myomo stock opened at $0.84 on Tuesday. The company has a current ratio of 2.73, a quick ratio of 2.36 and a debt-to-equity ratio of 1.21. The business has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $0.84. Myomo, Inc. has a 1-year low of $0.61 and a 1-year high of $3.45. The company has a market cap of $32.42 million, a P/E ratio of -2.33 and a beta of 1.39.
Wall Street Analyst Weigh In
Separately, Craig Hallum reiterated a “buy” rating on shares of Myomo in a report on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $7.67.
Hedge Funds Weigh In On Myomo
Institutional investors and hedge funds have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd bought a new position in shares of Myomo during the 1st quarter worth about $75,000. Invesco Ltd. bought a new position in shares of Myomo during the 2nd quarter worth about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Myomo during the 2nd quarter worth about $38,000. Acadian Asset Management LLC bought a new position in shares of Myomo during the 1st quarter worth about $114,000. Finally, Engineers Gate Manager LP boosted its position in shares of Myomo by 62.8% during the 2nd quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after purchasing an additional 11,614 shares in the last quarter. Institutional investors own 44.99% of the company’s stock.
Myomo Company Profile
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
Featured Articles
- Five stocks we like better than Myomo
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
